Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)

Clinical trial NCT03396445 · COMPLETED

Trial details

NCT number: NCT03396445
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pharmacokinetics Solid Tumor Carcinoma, Non-Small-Cell Lung Triple Negative Breast Neoplasms

Start date: 2018-02-18
Primary completion: 2024-09-27
Enrollment: 182

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.